Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Mach7 Technologies ( (AU:M7T) ).
Mach7 Technologies has announced the successful execution of Phase 1 of its collaboration with the Veterans Health Administration’s National Teleradiology Program, providing its Vendor Neutral Archive and eUnity Diagnostic Viewer. This phase, which has a potential contract value of A$11.7 million, marks a significant milestone for Mach7, highlighting its strengths in interoperability and cloud computing. The successful rollout could lead to further expansion into the VHA hospital network, enhancing diagnostic capabilities for veterans across 125 sites.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their Mach7 Enterprise Imaging Solution (EIS) includes a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, designed for flexibility and scalability to support a diverse range of healthcare networks.
Average Trading Volume: 226,580
Technical Sentiment Signal: Sell
Current Market Cap: A$66.97M
See more data about M7T stock on TipRanks’ Stock Analysis page.